These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24752949)

  • 1. The Vioxx® legacy: Enduring lessons from the not so distant past.
    McIntyre WF; Evans G
    Cardiol J; 2014; 21(2):203-5. PubMed ID: 24752949
    [No Abstract]   [Full Text] [Related]  

  • 2. Vioxx's history and the need for better procedures and better testing.
    Gilhooley M
    Seton Hall Law Rev; 2007; 37(4):941-68. PubMed ID: 18363218
    [No Abstract]   [Full Text] [Related]  

  • 3. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 4. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 5. Rofecoxib, Merck, and the FDA.
    Wolfe MM
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625749
    [No Abstract]   [Full Text] [Related]  

  • 6. Merck's Careful Study of Vioxx.
    Mayer TV
    Am J Cardiol; 2008 Apr; 101(7):1068-9; author reply 1069. PubMed ID: 18359336
    [No Abstract]   [Full Text] [Related]  

  • 7. What have we learnt from Vioxx?
    Krumholz HM; Ross JS; Presler AH; Egilman DS
    BMJ; 2007 Jan; 334(7585):120-3. PubMed ID: 17235089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of Vioxx.
    Garattini S; Bertelé V
    Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671
    [No Abstract]   [Full Text] [Related]  

  • 9. The Vioxx debacle revisited.
    Manthous CA
    Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904
    [No Abstract]   [Full Text] [Related]  

  • 10. Vioxx, the implosion of Merck, and aftershocks at the FDA.
    Horton R
    Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041
    [No Abstract]   [Full Text] [Related]  

  • 11. How the New England Journal missed warning signs on Vioxx: medical weekly waited years to report flaws in article that praised pain drug; Merck seen as "punching bag".
    Armstrong D
    Wall St J (East Ed); 2006 May; ():A1, A10. PubMed ID: 16848016
    [No Abstract]   [Full Text] [Related]  

  • 12. Discontinuation of Vioxx.
    Kim PS; Reicin AS
    Lancet; 2005 Jan 1-7; 365(9453):23; author reply 26-7. PubMed ID: 15639669
    [No Abstract]   [Full Text] [Related]  

  • 13. Adverse cardiovascular effects of rofecoxib.
    Furberg CD
    N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442
    [No Abstract]   [Full Text] [Related]  

  • 14. Adverse cardiovascular effects of rofecoxib.
    Nissen SE
    N Engl J Med; 2006 Jul; 355(2):203-4; author reply 203-5. PubMed ID: 16801355
    [No Abstract]   [Full Text] [Related]  

  • 15. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 16. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry.
    Cahana A; Mauron A
    J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707
    [No Abstract]   [Full Text] [Related]  

  • 17. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
    Mühlbauer B; Timm J
    Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".
    Luepker RV
    Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016
    [No Abstract]   [Full Text] [Related]  

  • 19. Unnecessary withdrawal of Vioxx.
    Adams D
    N Z Med J; 2004 Oct; 117(1204):U1130. PubMed ID: 15505673
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluating drug effects in the post-Vioxx world: there must be a better way.
    Avorn J
    Circulation; 2006 May; 113(18):2173-6. PubMed ID: 16684873
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.